AXL and non-small cell lung carcinoma: Kinase inhibitors of Axl increased phosphorylation of checkpoint kinases, while the combined treatment of NSCLC cells with Axl inhibitors and DDR-targeting Atr inhibitors significantly reduced NSCLC survival [78].